Nephrotic syndrome associated with interferon-β-1b therapy for multiple sclerosis

被引：22

作者：

Kumasaka R. ^{[1
]}

Nakamura N. ^{[1
]}

Shirato K. ^{[1
]}

Fujita T. ^{[1
]}

Murakami R. ^{[1
]}

Shimada M. ^{[1
]}

Nakamura M. ^{[1
]}

Osawa H. ^{[1
]}

Yamabe H. ^{[1
]}

Okumura K. ^{[1
]}

机构：

[1] Second Department of Internal Medicine, Hirosaki University, School of Medicine, Hirosaki, Aomori 036-8562

来源：

Clinical and Experimental Nephrology | 2006年 / 10卷 / 3期

关键词：

Interferon (IFN)-β-1b; Multiple sclerosis; Nephrotic syndrome; Proteinuria;

D O I：

10.1007/s10157-006-0424-9

中图分类号：

学科分类号：

摘要：

A 43-year-old woman with multiple sclerosis (MS) had nephrotic syndrome 21 months after starting treatment with interferon (IFN)-β-1b (subcutaneous administration). She had taken no drug except for the IFN-β-1b. Because nephrotic syndrome may be induced by IFN therapy, the IFN was stopped. Percutaneous renal biopsy revealed that she had minimal change nephrotic syndrome. As nephrotic-range proteinuria, hypoalbuminemia, and general edema were worsening even 2 weeks after cessation of the drug, oral corticosteroid therapy (prednisolone 40 mg/day) was started. The nephrotic syndrome was treated successfully with prednisolone. The dosage of prednisolone was tapered, without a relapse, and then the corticosteroid therapy was stopped. IFN-β-1b therapy was then resumed, and the patient is in remission for both nephrotic syndrome and MS. Though proteinuria and nephrotic syndrome is a rare adverse effect of IFN-β-1b therapy, physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings. © 2006 Japanese Society of Nephrology.

引用

页码：222 / 225

页数：3

共 13 条

[1] Compston A., Coles A., Multiple sclerosis, Lancet, 359, pp. 1221-31, (2002)
[2] Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial, Neurology, 43, pp. 655-61, (1993)
[3] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis, Lancet, 352, pp. 1498-504, (1998)
[4] Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis, Lancet, 352, pp. 1491-7, (1998)
[5] Randomized controlled trial of interferon-beta-1a in secondary progressive MS, Neurology, 56, pp. 1496-504, (2001)
[6] Bar-Or A., Oliveira E.M.L., Anderson D.E., Hafler D.A., Molecular pathogenesis of multiple sclerosis, J Neuroimmunol, 100, pp. 252-9, (1999)
[7] Trapp B.D., Bo L., Mork S., Chang A., Pathogenesis of tissue injury in MS lesions, J Neuroimmunol, 98, pp. 49-56, (1999)
[8] Jiang H., Milo R., Swoveland P., Johnson K.P., Panitch H., Dhib-Jalbut S., Interferon β-1b reduces interferon γ-induced antigen-presenting capacity of human glial and B cells, J Neuroimmunol, 61, pp. 17-25, (1995)
[9] Yong V.W., Chabot S., Stuve O., Williams G., Interferon beta in the treatment of multiple sclerosis: Mechanisms of action, Neurology, 51, pp. 682-9, (1998)
[10] Nakao K., Sugiyama H., Makino E., Matsuhara H., Ohmoto A., Sugimoto T., Et al., Minimal change nephrotic syndrome developing during postoperative interferon-beta therapy for malignant melanoma, Nephron, 90, pp. 498-500, (2002)

← 1 2 →